semaglutide and heart disease may help treat failure symptoms in type 2 diabetes Semaglutide Shows Direct Organ-Protective Benefits

In 2024, the FDA approved resmetirom (Rezdiffra) for adults with noncirrhotic NASH with F2F3 fibrosis, marking the first approved pharmacotherapy specifically for this condition

A cream dedicated to the area around the eyes, containing 1,000 ppm of tranexamic acid and glutathione, designed to lighten dark circles and improve the appearance of the skin around the eyes

2002 Aug;77(8):754-9

Multi-targeted mechanism: Simultaneously modulates three hormone pathways, potentially offering broader metabolic benefits (weight, glycemic control, liver fat) compared to dual/mono-agonists

Fortunately, several Qsymia clinics in Moncks Corner can provide clarity on this